Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013

The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acq This is hardly surprising with a global injectables market in the region of US$144 billion. While the lion’s share remains with the innovative industry for the time chemical generics and will involve costly clinical trials. To date, only a handful of companies have gained regulatory approval for biosimilars in Europe, and the US is lik This report features in-depth reviews of 35 major products within specific therapy areas. Each product review examines mode of action, market approvals, competition, What this report covers: Executive Summary Injectable Drugs Market – Market Size and Opportunities Cancer – Hormonal Therapies, Chemotherapy, Monoclonal Antibodies, S The Injectable Generic and Biosimilar Drugs Report is the foolproof business resource for any industry executive that needs to fully understand the current products and table Of Content

foreword

executive Summary

injectable Drugs Market market Size generic And Biosimilar Opportunities

cancer

hormonal Therapies faslodex (fulvestrant) mode Of Action approvals lifecycle Development competition Within The Marketplace patents market Outlook generic Company Activity zoladex (goserelin) mode Of Action approvals competition Within The Marketplace breast Cancer prostate Cancer patents market Outlook generic Company Activity europe north America

chemotherapy eloxatin (oxaliplatin) mode Of Action approvals competition Within The Marketplace patents market Outlook generic Company Activity the ‘874 Patent Litigation: At Risk Launches And Subsequent Withdrawals europe taxotere (docetaxel) mode Of Action approvals competition Within The Marketplace patents market Outlook generic Company Activity europe us abraxane (paclitaxel Protein-bound Particles For Injectable Suspension; Albumin-bound) mode Of Action approvals...